Table 4.
Regions | N | Failure number | Factors | |
---|---|---|---|---|
Narita et al. 45 | Europe | 80 | 29 | 1. Number of CLM in FLR ≥ 3 |
2. Age > 70 yr | ||||
Giuliante et al. 60 | Europe | 130 | 28 | 1. Tumor progression during chemotherapy* |
Imai et al. 96 | Europe | 125 | 44 | 1. CEA > 30 ng/mL |
2. Largest CLM diameter > 4 cm | ||||
3. Preoperative chemotherapy > 12 cycles | ||||
4. Tumor progression during chemotherapy | ||||
Passot et al. 48 | USA | 109 | 20 | 1. Number of CLM > 5 |
2. Largest CLM diameter > 5 cm | ||||
3. Preoperative chemotherapy > 6 cycles | ||||
4. PVE | ||||
5. Major complication after the first stage |
Abbreviations: CLM, colorectal liver metastasis; FLR, future liver remnant; CEA, carcinoembryonic antigen; PVE, portal vein embolization.
Analyzed in 126 patients after excluding